2025 AGENDA COMING SOON | Kisaco Research

2025 AGENDA COMING SOON

Advanced Wound Care USA
15-16 July, 2025
Boston, USA

REGISTER YOUR INTEREST

Be part of the community shaping the future of wound care at the 4th Advanced Wound Care Summit USA 2025, the only industry-led summit of its kind.

DEDICATED TRACKS
Separate tracks dedicated to R&D and Commercialisation, allow you to gain cross-functional insights, and unlock practical strategies across comprehensive aspects of wound care from biologics, diagnostics, managing bioburden, clinical trial design, and business development.

MORE NETWORKING OPPORTUNITIES
Take advantage of our carefully curated room of industry experts. Meet with investors, distributors, and payers, building strategic partnerships to elevate your product for market success.

MARKET INSIGHTS 
Understand current trends and challenges throughout the wound care industry from expert expert-led presentations, panel discussions, and intimate round tables on reimbursement, regulation, M&A strategy, and investment trends to inform your business strategy. 

UNPARALLELED INNOVATION 
Offering a unique platform for those seeking their next partnership or acquisition to accelerate business growth by joining the latest and leading start-ups as they pitch their innovations at our Innovation Showcase.

Register your interest and be the first to get updates!

Let us know you'd like to hear more by filling out this form...

AGENDA SNEAK PEEK

Filter by:

Here's a sneak peek of our 2024 agenda... Download our full agenda below to find out more!

Printable version

Tuesday, 16 Apr, 2024
9:00am

Shaping the Future of Advanced Wound Care

  • Investigate cutting-edge wound care tech and personalized medicine.
  • Navigate changing regulations, prioritize standardized protocols, and promote patient engagement through education and home-based care.
  • Evaluate economic impacts, enhance reimbursement models, and address accessibility challenges

Author:

Kevin Richardson

Chief Strategic Officer
SANUWAVE
... read more

Kevin Richardson

Chief Strategic Officer
SANUWAVE

Author:

Emma Wright

CMO
Mölnlycke

Emma is an industry professional with 25 years of experience in medical devices in both start-up and international companies, based in UK, US and most recently in Sweden.  Her career has been focused on the development and commercialisation of devices in wound care, reconstructive surgery and orthopedics with a specific interest in products that actively promote tissue repair.  In the last 10 years Emma has led clinical, medical and health economic teams with responsibility for clinical evidence generation, professional education, medical affairs and health economics. 

... read more

Emma Wright

CMO
Mölnlycke

Emma is an industry professional with 25 years of experience in medical devices in both start-up and international companies, based in UK, US and most recently in Sweden.  Her career has been focused on the development and commercialisation of devices in wound care, reconstructive surgery and orthopedics with a specific interest in products that actively promote tissue repair.  In the last 10 years Emma has led clinical, medical and health economic teams with responsibility for clinical evidence generation, professional education, medical affairs and health economics. 

Author:

Kris Kieswetter

Senior Director, Research and Technology
3M
... read more

Kris Kieswetter

Senior Director, Research and Technology
3M
9:40am

Shaping the Future of Advanced Wound Care

  • Emphasize the importance of regulatory bodies adapting to facilitate swift approvals for evolving wound care innovations, aligning standards with technology advancements.
  • Explore the mutually beneficial link between regulatory backing and industry growth

Author:

Julie Morabito

Assistant Director
FDA

Assistant Director, Division of Infection Control and Plastic and Reconstructive Surgery at FDA’s Center for Devices and Radiological Health (CDRH). (Plastic Surgery Skin and Wound Devices Team).

... read more

Julie Morabito

Assistant Director
FDA

Assistant Director, Division of Infection Control and Plastic and Reconstructive Surgery at FDA’s Center for Devices and Radiological Health (CDRH). (Plastic Surgery Skin and Wound Devices Team).

20:50am

R&D TRACK: Current Perspectives on Biologics in Wound Care

  • Examine biologics' effectiveness in wound care through current research, emphasizing improved patient outcomes and accelerated healing.
  • Discuss personalized medicine integration in wound care
  • Address current landscape challenges, including protocol standardization, regulatory considerations and economic implications

Author:

Jaideep Banerjee

Lead Medical Science Liaisons and Clinical Strategy
Smith & Nephew
... read more

Jaideep Banerjee

Lead Medical Science Liaisons and Clinical Strategy
Smith & Nephew

COMMERCIALIZATION TRACK: Exploring Investment in the Advanced Wound Care Space

  • Investigate current trends and opportunities, spotlighting investor interests and factors influencing investment decisions.
  • Discuss risk mitigation strategies in the sector, emphasizing thorough due diligence, market analysis, and regulatory understanding
  • Highlight collaboration potential between investors and industry stakeholders

Author:

Artem Trotsyuk

Venture Partner
LongeVC
... read more

Artem Trotsyuk

Venture Partner
LongeVC

Author:

Ibraheem Badejo

Senior R&D Director, External Front End Innovation
Johnson & Johnson

Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.

From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.

During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.

Ib received his BA degree in chemistry from Avila University.  He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending

... read more

Ibraheem Badejo

Senior R&D Director, External Front End Innovation
Johnson & Johnson

Ibraheem (Ib) is Senior R&D Director, External Front End Innovation at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.

From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.

During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.

Ib received his BA degree in chemistry from Avila University.  He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending